Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Pharmaceutical Manufacturing	184.33M	202.97M	310.46M	308.45M	447.34M
Pharmaceutical Manufacturing Growth	-9.18%	-34.62%	0.65%	-31.05%	-7.78%
Pharmaceutical Wholesale and Retail	36.35M	144.04M	204.09M	220.96M	183.84M
Pharmaceutical Wholesale and Retail Growth	-74.77%	-29.43%	-7.63%	20.19%	34.49%
Unallocated Other Operating Revenue/Costs	-	4.19M	5.07M	3.03M	1.77M
Unallocated Other Operating Revenue/Costs Growth	-	-17.26%	67.09%	71.27%	80.63%
Other Operating Revenue/Costs	4.60M	-	-	-	-
Total	225.27M	351.20M	519.62M	532.44M	632.95M
Total Growth	-35.86%	-32.41%	-2.41%	-15.88%	1.64%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	225.27M	351.20M	519.62M	532.44M	632.95M
China Growth	-35.86%	-32.41%	-2.41%	-15.88%	1.64%
Total	225.27M	351.20M	519.62M	532.44M	632.95M
Total Growth	-35.86%	-32.41%	-2.41%	-15.88%	1.64%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 11, 2026

Data Sources Report a data error